The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region
Issued Date
2023-11-01
Resource Type
eISSN
2214109X
Scopus ID
2-s2.0-85174161478
Journal Title
The Lancet Global Health
Volume
11
Issue
11
Start Page
e1805
End Page
e1818
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet Global Health Vol.11 No.11 (2023) , e1805-e1818
Suggested Citation
Unger H.W., Acharya S., Arnold L., Wu C., van Eijk A.M., Gore-Langton G.R., ter Kuile F.O., Lufele E., Chico R.M., Price R.N., Moore B.R., Thriemer K., Rogerson S.J. The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region. The Lancet Global Health Vol.11 No.11 (2023) , e1805-e1818. e1818. doi:10.1016/S2214-109X(23)00415-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/90715
Title
The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region
Author's Affiliation
Curtin Medical School
Mahidol Oxford Tropical Medicine Research Unit
Perth Children's Hospital
The Peter Doherty Institute for Infection and Immunity
The Faculty of Health Sciences
Papua New Guinea Institute of Medical Research
London School of Hygiene & Tropical Medicine
University of Melbourne
Menzies School of Health Research
Liverpool School of Tropical Medicine
Nuffield Department of Medicine
Royal Darwin Hospital
Mahidol Oxford Tropical Medicine Research Unit
Perth Children's Hospital
The Peter Doherty Institute for Infection and Immunity
The Faculty of Health Sciences
Papua New Guinea Institute of Medical Research
London School of Hygiene & Tropical Medicine
University of Melbourne
Menzies School of Health Research
Liverpool School of Tropical Medicine
Nuffield Department of Medicine
Royal Darwin Hospital
Other Contributor(s)
Abstract
Half of all pregnancies at risk of malaria worldwide occur in the Asia–Pacific region, where Plasmodium falciparum and Plasmodium vivax co-exist. Despite substantial reductions in transmission, malaria remains an important cause of adverse health outcomes for mothers and offspring, including pre-eclampsia. Malaria transmission is heterogeneous, and infections are commonly subpatent and asymptomatic. High-grade antimalarial resistance poses a formidable challenge to malaria control in pregnancy in the region. Intermittent preventive treatment in pregnancy reduces infection risk in meso-endemic New Guinea, whereas screen-and-treat strategies will require more sensitive point-of-care tests to control malaria in pregnancy. In the first trimester, artemether–lumefantrine is approved, and safety data are accumulating for other artemisinin-based combinations. Safety of novel antimalarials to treat artemisinin-resistant P falciparum during pregnancy, and of 8-aminoquinolines during lactation, needs to be established. A more systematic approach to the prevention of malaria in pregnancy in the Asia–Pacific is required.